A5076551658- Venous Thromboembolism Diagnosis and Management
- Platelet Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- Inflammatory Biomarkers in Disease Prognosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune cells in cancer
- Central Venous Catheters and Hemodialysis
- COVID-19 and healthcare impacts
- Cancer Treatment and Pharmacology
- Atrial Fibrillation Management and Outcomes
- Cardiac tumors and thrombi
- COVID-19 Clinical Research Studies
- Cancer, Lipids, and Metabolism
- Prostate Cancer Treatment and Research
- Advanced Breast Cancer Therapies
- Systemic Sclerosis and Related Diseases
- Hematological disorders and diagnostics
- Blood disorders and treatments
- S100 Proteins and Annexins
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Breast Cancer Treatment Studies
- Infection Control and Ventilation
- Bone and Joint Diseases
Memorial Sloan Kettering Cancer Center
2017-2024
Cornell University
2023-2024
NewYork–Presbyterian Hospital
2023
New York Hospital Queens
2023
Presbyterian Hospital
2023
CancerCare
2023
Weill Cornell Medicine
2023
Keck Hospital of USC
2013
Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment.We conducted a phase II randomized trial of romiplostim versus untreated observation patients with solid tumors CIT. Before enrollment, had platelets less than 100,000/μL for at least 4 weeks, despite dose chemotherapy. Patients received weekly titrated target platelet count more, were monitored usual care. The primary end point was correction within 3 weeks....
Leukocytosis is a common feature of malignancies. While controversial, there appears to be an association between the degree tumor-related leukocytosis and prognosis. In this paper, we provide evidence supporting untapped clinical paradigm linking G-CSF secretion induction expansion myeloid-derived suppressor cells, providing explanation for leukocytosis, elevated neutrophil-to-lymphocyte ratios prognosis in non-small cell lung cancer. Clinically validating mechanism may identify MDSCs as...
Summary Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use direct oral anticoagulants as thromboprophylaxis setting haematologic malignancies, specifically myeloma. In this retrospective study 305 NDMM patients, VTE rates those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, (RVD) ASA, and KRD rivaroxaban were statistically significant, 16·1%,...
Low-molecular-weight heparin has been the preferred treatment of cancer-associated thrombosis (CAT); however, emerging data support use direct oral anticoagulants (DOACs).The Memorial Sloan Kettering Cancer Center Clinical Pathway served as institutional guideline for rivaroxaban to treat CAT since 2014. Key elements are recommend against a DOAC in patients with active gastrointestinal (GI) or genitourinary tract lesions, and prespecified dose reduction elderly (75+ years old). We present...
Importance Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. Objective To assess therapy exposure within 3 months prior to TEEs following diagnosis cancer. Design, Setting, Participants This registry-based retrospective cohort study included who were hospitalized had active cancer laboratory-confirmed SARS-CoV-2 infection. Data accrued from March 2020 December 2021 analyzed October 2022. Exposure Treatments...
Romiplostim is used to treat chemotherapy-induced thrombocytopenia in a variety of tumor types; however, few studies have examined its use breast and gynecologic cancers. We evaluated platelet response durability romiplostim patients with or cancer complicated by thrombocytopenia. retrospectively identified 33 who received between 07/1/2021–07/31/2022 at an academic center. Thirty-three met inclusion criteria; 26 (79 %) had cancer, 4 (12 ovarian 3 (9 endometrial cancer. Twenty (61...
You have accessJournal of UrologyCME1 May 2022MP35-10 THE IMPACT OF PAP THERAPY ON HEMATOCRIT IN OSA AND POLYCYTHEMIA: A PILOT STUDY Mustafa Jafri, Gabrielle Rosa-Acosta, Jose Flores Martinez, Elizabeth Schofield, Cy Wilkins, John Mulhall, and Miranda Tan JafriMustafa Jafri More articles by this author , Rosa-AcostaGabrielle Rosa-Acosta MartinezJose Martinez SchofieldElizabeth Schofield WilkinsCy Wilkins MulhallJohn Mulhall TanMiranda View All Author...
Abstract Introduction Untreated polycythemia leads to complications including thrombosis. Obstructive sleep apnea (OSA) is commonly associated with secondary erythrocytosis, which testosterone therapy can perpetuate. Effects of positive airway pressure (PAP) on elevated hematocrit (HCT) unknown. We hypothesize PAP adherence reduce HCT in men OSA and polycythemia. Methods Retrospective chart review male outpatients newly diagnosed HCT≥45% at or 3 months before polysomnography (PSG) was...